Evaluation of Blood Soluble CD26 as a Complementary Biomarker for Colorectal Cancer Screening Programs

Evaluation of Blood Soluble CD26 as a Complementary Biomarker for Colorectal Cancer Screening Programs

Fecal hemoglobin immunodetection (FIT) in combination with endoscopy has been implemented to reduce mortality from colorectal cancer (CRC), although there are issues that can be improved in relation to participation rates. We studied whether the blood biomarker soluble-CD26 (sCD26), related at least...

Full description

Bibliographic Details
Main Authors: Loretta De Chiara, Leticia Barcia-Castro, María Gallardo-Gómez, María Páez de la Cadena, Vicenta S. Martínez-Zorzano, Francisco J. Rodríguez-Berrocal, Luis Bujanda, Ane Etxart, Antoni Castells, Francesc Balaguer, Rodrigo Jover, Joaquín Cubiella, Oscar J. Cordero
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cancers
Subjects:
colorectal cancer
advanced adenomas
FIT
endoscopy
blood test
soluble CD26
Online Access:https://www.mdpi.com/2072-6694/14/19/4563

Internet

https://www.mdpi.com/2072-6694/14/19/4563

Similar Items